BioAge Labs (BIOA) said Tuesday it terminated the development of azelapra after elevated levels of certain liver enzymes were recorded in the blood of some patients in a phase 2 clinical study for obesity.
The company said it is developing structurally distinct APJ agonists and plans to finalize a development candidate by the end of 2025.
BGE-102 is under development for the treatment of neuroinflammation and phase 1 single ascending dose data is expected by the end of the year, BioAge said.
Price: 5.29, Change: -0.09, Percent Change: -1.58
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.